Business Description
Roche Holding AG
NAICS : 325412
SIC : 2834
ISIN : CH0012032048
Share Class Description:
FRA:RHO5: Ordinary SharesDescription
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.34 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.05 | |||||
| Debt-to-EBITDA | 1.66 | |||||
| Interest Coverage | 15.44 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.89 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.7 | |||||
| 3-Year EBITDA Growth Rate | -4.7 | |||||
| 3-Year EPS without NRI Growth Rate | -1 | |||||
| 3-Year FCF Growth Rate | 1.2 | |||||
| 3-Year Book Growth Rate | -4.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 4.25 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 1.04 | |||||
| Cash Ratio | 0.42 | |||||
| Days Inventory | 184.84 | |||||
| Days Sales Outstanding | 70.15 | |||||
| Days Payable | 85.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 1.8 | |||||
| 3-Year Average Share Buyback Ratio | 2.2 | |||||
| Shareholder Yield % | 4.38 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.94 | |||||
| Operating Margin % | 25.47 | |||||
| Net Margin % | 19.02 | |||||
| FCF Margin % | 18.93 | |||||
| ROE % | 41.15 | |||||
| ROA % | 13.12 | |||||
| ROIC % | 18.37 | |||||
| ROC (Joel Greenblatt) % | 60.53 | |||||
| ROCE % | 24.48 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.72 | |||||
| Forward PE Ratio | 12.8 | |||||
| PE Ratio without NRI | 12.12 | |||||
| Shiller PE Ratio | 16.21 | |||||
| Price-to-Owner-Earnings | 15.83 | |||||
| PEG Ratio | 10.1 | |||||
| PS Ratio | 2.99 | |||||
| PB Ratio | 6.12 | |||||
| Price-to-Tangible-Book | 35.19 | |||||
| Price-to-Free-Cash-Flow | 15.81 | |||||
| Price-to-Operating-Cash-Flow | 11.24 | |||||
| EV-to-EBIT | 13.36 | |||||
| EV-to-EBITDA | 10.87 | |||||
| EV-to-Revenue | 3.33 | |||||
| EV-to-FCF | 17.6 | |||||
| Price-to-Projected-FCF | 1.13 | |||||
| Price-to-DCF (Earnings Based) | 0.79 | |||||
| Price-to-DCF (FCF Based) | 1.03 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Graham-Number | 4.35 | |||||
| Earnings Yield (Greenblatt) % | 7.49 | |||||
| FCF Yield % | 6.32 | |||||
| Forward Rate of Return (Yacktman) % | 8.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roche Holding AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 63,009.72 | ||
| EPS (TTM) (€) | 14.861 | ||
| Beta | 0 | ||
| Volatility % | 3.92 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 245.6 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 245.6 - 245.6 | ||
| Shares Outstanding (Mil) | 797.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roche Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roche Holding AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roche Holding AG Frequently Asked Questions
What is Roche Holding AG(FRA:RHO5)'s stock price today?
The current price of FRA:RHO5 is €245.60. The 52 week high of FRA:RHO5 is €245.60 and 52 week low is €245.60.
When is next earnings date of Roche Holding AG(FRA:RHO5)?
The next earnings date of Roche Holding AG(FRA:RHO5) is 2024-07-26 Est..
Does Roche Holding AG(FRA:RHO5) pay dividends? If so, how much?
Roche Holding AG(FRA:RHO5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers